David Szymkowski
Equibles does not estimate personal net worth.
About David Szymkowski
Earlier roles on record: Board Member at Inmune Bio, Inc. (INMB) until June 10, 2021. Inmune Bio, Inc. reported in an 8-K filed June 15, 2021 that David Szymkowski resigned as Board of Directors. The same filing states: “Mr. Szymkowski did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices.” Inmune Bio, Inc. reported in an 8-K filed June 15, 2021 that David Szymkowski resigned as member of the board of directors, effective June 10, 2021. The same filing states: “Mr. Szymkowski did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices.”
“Concurrent with this transaction, David Szymkowski, Ph.D., Vice President of Preclinical Operations at Xencor, stepped down from INmune’s Board of Directors.”
“Mr. Szymkowski did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices.”
“On June 10, 2021 David Szymkowski resigned as a member of the board of directors of the Company.”
“Mr. Szymkowski did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices.”
Affiliation history
-
2018-01-01–2021-06-10
Company network
Recent activity
-
Executive change Resigned: Board of Directors
“Mr. Szymkowski did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices.”
Inmune Bio, Inc. (INMB) -
Executive change Resigned: member of the board of directors
“Mr. Szymkowski did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices.”
Inmune Bio, Inc. (INMB)